Success Metrics

Active Trials
4(50%)

Phase Distribution

Ph phase_3
2
25%
Ph phase_4
1
13%
Ph phase_1
1
13%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Not yet recruiting4
Active, not recruiting4

Development Timeline

Analytics

Development Status

Total Trials
8
Active
4
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

not_yet_recruiting450%
active_not_recruiting450%

Recent Activity

4 active trials
Showing 5 of 8
not_yet_recruiting

Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset

NCT07235397
active_not_recruitingphase_4

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

NCT06551506
not_yet_recruitingphase_1

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

NCT07492706
active_not_recruiting

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

NCT07249320
active_not_recruiting

STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)

NCT07122661
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07235397

Evaluating the Benefits of RSV Maternal Vaccination Using a Scottish National Dataset

Not Yet Recruiting
NCT06551506Phase 4

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

Active Not Recruiting
NCT07492706Phase 1

Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

Not Yet Recruiting
NCT07249320

Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants

Active Not Recruiting
NCT07122661

STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in Hospitalised Infants in Australia (STREETON)

Active Not Recruiting
NCT07232706Phase 3

Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination

Not Yet Recruiting
NCT06647654

Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy

Active Not Recruiting
NCT07041190Phase 3

Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.

Not Yet Recruiting

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8